PHARMACEUTICAL 2013

ELI Lilly Co
Rank 93 of 218



RealRate

PHARMACEUTICAL 2013

ELI Lilly Co
Rank 93 of 218

Lilly

The relative strengths and weaknesses of ELI Lilly Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI Lilly Co compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 76% points.The greatest weakness of ELI Lilly Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 257%, being 36% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	13,038,700
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,389,500
Liabilities, Non-Current	11,235,500
Other Assets	13,600,000
Other Compr. Net Income	61,500
Other Expenses	5,723,200
Other Liabilities	0
Other Net Income	0
Other Revenues	22,603,400
Property and Equipment	7,760,200
Research and Development	5,278,100
Selling, General and Administrative Expense	7,513,500

Output Variable	Value in 1000 USD
Assets	34,398,900
Liabilities	19,625,000
Expenses	18,514,800
Revenues	22,603,400
Stockholders Equity	14,773,900
Net Income	4,088,600
Comprehensive Net Income	4,119,350
BaseVar	47,601,800
ECR before LimitedLiability	134%
Economic Capital Ratio	257%